Attention-Deficit/Hyperactivity Disorder Archives

Maternal use of valproic acid during pregnancy may increase risk of autism spectrum disorders (ASD) and attention-deficit and hyperactivity disorder (ADHD) in offspring.

General Neurology

Understanding the Underlying Neurobiology Behind Group Differences in Cortical Thickness Across Psychiatric Disorders

By

Emily Pond

October 6, 2020

This study highlights the importance of transdiagnostic approaches to psychiatry.

Neurobehavioral Disorders

Neuropsychiatric Disorders Up in Offspring of Mothers With PCOS

September 8, 2020

Exposure to maternal polycystic ovary syndrome is associated with increased risk of a range of neurodevelopmental and psychiatric disorders in offspring.

Sleep Disorders

Comorbid ADHD, Insomnia Associated With Poorer Mental Functioning, Productivity

By

Emily Pond

August 18, 2020

The combined burden of ADHD and insomnia may play a unique role in mental functioning and productivity, even after adjustment for other psychiatric comorbidities.

Neurobehavioral Disorders

ENIGMA Study Finds Age Related Cortical Differences in ADHD, ASD, and OCD

By

Jessica Nye

July 28, 2020

Despite being common and often comorbid neurodevelopmental disorders, the study found robust yet subtle differences across age groups and the disorders in terms of cortical and subcortical brain structures.

Sleep Disorders

Insomnia and Alcohol Consumption Linked to ADHD Symptoms

By

Emily Pond

July 7, 2020

Among adults without a clinical diagnosis of ADHD, heavy alcohol use predicted more severe ADHD symptoms.

Neurobehavioral Disorders

FDA Clears Video Game-Based Therapy for Pediatric ADHD

By

Brian Park, PharmD

June 18, 2020

The FDA has cleared EndeavorRxTM for use as a prescription-only video game-based digital therapeutic to improve attention function in pediatric patients aged 8-12 years with primarily inattentive or combined-type ADHD.

Neurobehavioral Disorders

Triple Reuptake Inhibitor Improves AISRS Score in Adult ADHD

By

Brian Park, PharmD

June 17, 2020

The two, 6-week, multicenter, double-blind, placebo-controlled trials (Study 1 and Study 2) evaluated the efficacy and safety of centanafadine sustained-release tablets in approximately 900 adult patients with ADHD.